Talphera (TLPH) Other financing activities (2011 - 2026)

Talphera (TLPH) posted quarterly Other financing activities of $4.0 million for Q1 2026, up 190.5% quarter-over-quarter from $1.4 million in Q4 2025.

Talphera (TLPH) Other financing activities (2011 - 2026) Analysis & Trends

Talphera's Other financing activities history runs 11 years deep, the most recent figure standing at $4.0 million for Q1 2026.

In Q1 2026, Other financing activities changed N/A year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $26.8 million (changed N/A YoY), while the FY2025 annual figure was $22.7 million, up 286.18% from the prior year.
Other financing activities for Q1 2026 stood at $4.0 million, up from $1.4 million in the prior quarter.
The five-year high for Other financing activities was $17.0 million in Q3 2025, with the low at -$22000.0 in Q4 2023.
The 5-year median for Other financing activities is $724000.0 (2022), against an average of $3.3 million.
The sharpest annual moves came in 2022 and 2024: Other financing activities sank 86.89% in 2022, then jumped 18880.65% in 2024.
Talphera's Other financing activities stood at $16000.0 in 2022, then plunged by 237.5% to -$22000.0 in 2023, then soared by 26845.45% to $5.9 million in 2024, then tumbled by 76.38% to $1.4 million in 2025, then jumped by 190.5% to $4.0 million in 2026.
Business Quant data shows TLPH's Other financing activities at $4.0 million in Q1 2026, $1.4 million in Q4 2025, and $17.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.85 Bn	42.88 Bn	-
2	Teva Pharmaceutical Industries	43.02 Bn	39.37 Bn	2.15 Bn
3	Zoetis	31.47 Bn	29.79 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.59 Bn	22.79 Bn	5.10 Bn
5	United Therapeutics	22.20 Bn	19.53 Bn	683.80 Mn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn
7	Neurocrine Biosciences	15.45 Bn	15.06 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-
10	Talphera	90.25 Mn	90.25 Mn	-

Download Data